Skip to main content
. Author manuscript; available in PMC: 2024 Mar 1.
Published in final edited form as: Arch Dermatol Res. 2022 Feb 26;315(2):305–315. doi: 10.1007/s00403-022-02325-3

Fig 2.

Fig 2.

Clinical images from subjects with self-reported improvement Representative images from three subjects (top: CIE (800–6); middle: NS (800–9); bottom: NS (801–1)) at baseline and after 16 weeks on secukinumab. These subjects were among the five who noted reduced erythema and/or scaling and chose to continue secukinumab after trial completion